Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
IEEE

Deadlock Resolution and Recursive Feasibility in MPC-Based Multirobot Trajectory Generation

Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...
IEEE

Recursive Deformable Pyramid Network for Unsupervised Medical Image Registration

Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...